Impact of influenza vaccination on amoxicillin prescriptions in older adults: A retrospective cohort study using primary care data.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
11
2020
accepted:
15
01
2021
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
23
6
2021
Statut:
epublish
Résumé
Bacterial infections of the upper and lower respiratory tract are a frequent complication of influenza and contribute to the widespread use of antibiotics. Influenza vaccination may help reduce both appropriate and inappropriate prescribing of antibiotics. Electronic health records provide a rich source of information for assessing secondary effects of influenza vaccination. We conducted a retrospective study to estimate effects of influenza vaccine on antibiotic (amoxicillin) prescription in the elderly based on data from the Clinical Practice Research Datalink. The introduction of UK policy to recommend the influenza vaccine to older adults in 2000 led to a substantial increase in uptake, creating a natural experiment. Of 259,753 eligible patients that were unvaccinated in 1999 and aged≥65y by January 2000, 88,519 patients received influenza vaccination in 2000. These were propensity score matched 1:1 to unvaccinated patients. Time-to-amoxicillin was analysed using the Prior Event Rate Ratio (PERR) Pairwise method to address bias from time-invariant measured and unmeasured confounders. A simulation study and negative control outcome were used to help strengthen the validity of results. Compared to unvaccinated patients, those from the vaccinated group were more likely to be prescribed amoxicillin in the year prior to vaccination: hazard ratio (HR) 1.90 (95% confidence interval 1.83, 1.98). Following vaccination, the vaccinated group were again more likely to be prescribed amoxicillin, HR 1.64 (1.58,1.71). After adjusting for prior differences between the two groups using PERR Pairwise, overall vaccine effectiveness was 0.86 (0.81, 0.92). Additional analyses suggested that provided data meet the PERR assumptions, these estimates were robust. Once differences between groups were taken into account, influenza vaccine had a beneficial effect, lowering the frequency of amoxicillin prescribing in the vaccinated group. Ensuring successful implementation of national programmes of vaccinating older adults against influenza may help contribute to reducing antibiotic resistance.
Sections du résumé
BACKGROUND
Bacterial infections of the upper and lower respiratory tract are a frequent complication of influenza and contribute to the widespread use of antibiotics. Influenza vaccination may help reduce both appropriate and inappropriate prescribing of antibiotics. Electronic health records provide a rich source of information for assessing secondary effects of influenza vaccination.
METHODS
We conducted a retrospective study to estimate effects of influenza vaccine on antibiotic (amoxicillin) prescription in the elderly based on data from the Clinical Practice Research Datalink. The introduction of UK policy to recommend the influenza vaccine to older adults in 2000 led to a substantial increase in uptake, creating a natural experiment. Of 259,753 eligible patients that were unvaccinated in 1999 and aged≥65y by January 2000, 88,519 patients received influenza vaccination in 2000. These were propensity score matched 1:1 to unvaccinated patients. Time-to-amoxicillin was analysed using the Prior Event Rate Ratio (PERR) Pairwise method to address bias from time-invariant measured and unmeasured confounders. A simulation study and negative control outcome were used to help strengthen the validity of results.
RESULTS
Compared to unvaccinated patients, those from the vaccinated group were more likely to be prescribed amoxicillin in the year prior to vaccination: hazard ratio (HR) 1.90 (95% confidence interval 1.83, 1.98). Following vaccination, the vaccinated group were again more likely to be prescribed amoxicillin, HR 1.64 (1.58,1.71). After adjusting for prior differences between the two groups using PERR Pairwise, overall vaccine effectiveness was 0.86 (0.81, 0.92). Additional analyses suggested that provided data meet the PERR assumptions, these estimates were robust.
CONCLUSIONS
Once differences between groups were taken into account, influenza vaccine had a beneficial effect, lowering the frequency of amoxicillin prescribing in the vaccinated group. Ensuring successful implementation of national programmes of vaccinating older adults against influenza may help contribute to reducing antibiotic resistance.
Identifiants
pubmed: 33513169
doi: 10.1371/journal.pone.0246156
pii: PONE-D-20-35449
pmc: PMC7846013
doi:
Substances chimiques
Influenza Vaccines
0
Amoxicillin
804826J2HU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246156Subventions
Organisme : Medical Research Council
ID : G0902158
Pays : United Kingdom
Déclaration de conflit d'intérêts
WH has a personal long-term shareholding in Glaxo Wellcome, who manufacture an influenza vaccine. WEH has previously received funding from IQVIA. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
PLoS One. 2011;6(7):e22618
pubmed: 21818350
BMC Med. 2019 Jan 10;17(1):9
pubmed: 30626399
Vaccine. 2017 Nov 1;35(46):6269-6274
pubmed: 29032898
Vaccine. 2018 Sep 5;36(37):5556-5564
pubmed: 30076104
MMWR Recomm Rep. 2005 Jul 29;54(RR-8):1-40
pubmed: 16086456
Am J Epidemiol. 2001 Jul 15;154(2):155-60
pubmed: 11447049
JAMA. 1994 Dec 7;272(21):1661-5
pubmed: 7966893
Vaccine. 2014 Mar 10;32(12):1323-5
pubmed: 24486359
Curr Opin Immunol. 2014 Aug;29:38-42
pubmed: 24769424
Int J Epidemiol. 2010 Feb;39(1):107-17
pubmed: 19948779
Vaccine. 2017 Dec 19;35(52):7297-7301
pubmed: 29146382
Pediatr Infect Dis J. 2009 Oct;28(10):855-9
pubmed: 19564812
BMJ Open. 2017 Aug 18;7(8):e016023
pubmed: 28821521
Value Health. 2010 Jan-Feb;13(1):132-7
pubmed: 19695007
Int J Epidemiol. 2006 Apr;35(2):345-52
pubmed: 16368724
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876
pubmed: 20166072
JAMA Netw Open. 2018 Jun 1;1(2):e180243
pubmed: 30646067
J Clin Epidemiol. 2020 Jun;122:78-86
pubmed: 32194148
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901
pubmed: 30559195
BMJ Open. 2012 Mar 15;2(2):e001019
pubmed: 22422920
Stat Med. 2020 Feb 28;39(5):639-659
pubmed: 31788843
J Antimicrob Chemother. 2019 Nov 1;74(11):3371-3378
pubmed: 31430365
Int J Infect Dis. 2014 Jul;24:40-2
pubmed: 24815741
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:60-8
pubmed: 22552981
J Clin Epidemiol. 2009 Jul;62(7):687-94
pubmed: 19124221
Int J Clin Pharm. 2016 Jun;38(3):714-23
pubmed: 27091131
BMJ Open. 2020 Jun 22;10(6):e038767
pubmed: 32571866
Arch Intern Med. 2012 Mar 26;172(6):484-91
pubmed: 22371873
J Clin Epidemiol. 2017 Jul;87:23-34
pubmed: 28460857
J Clin Epidemiol. 2014 Jul;67(7):734-44
pubmed: 24768004
Vaccine. 2009 Oct 23;27(45):6300-4
pubmed: 19840664
J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8
pubmed: 17163383
J Clin Epidemiol. 2009 Jan;62(1):22-8
pubmed: 18619797
Int J Antimicrob Agents. 2007 Feb;29 Suppl 1:S6-10
pubmed: 17307654
Ann Intern Med. 1995 Oct 1;123(7):518-27
pubmed: 7661497
Pediatr Infect Dis J. 2020 Jan;39(1):e1-e10
pubmed: 31725115
Int J Epidemiol. 2006 Jun;35(3):800-2; author reply 799-800
pubmed: 16618708
Chest. 2018 Nov;154(5):1202-1212
pubmed: 29959904
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S110-21
pubmed: 23849144
PLoS Med. 2013 Oct;10(10):e1001527
pubmed: 24115913
Eur Respir J. 2009 Jul;34(1):56-62
pubmed: 19213779
Stat Med. 2016 Dec 10;35(28):5149-5169
pubmed: 27477530
J Antimicrob Chemother. 2018 Mar 1;73(3):779-786
pubmed: 29228207
Clin Infect Dis. 2009 Sep 1;49(5):750-6
pubmed: 19624280
Pharmacoepidemiol Drug Saf. 2015 May;24(5):468-77
pubmed: 25410590
Vaccine. 2016 Sep 7;34(39):4645-6
pubmed: 27578296